EU side-effects database expanded

Published: 19-Nov-2014
Regulatory

To cover nationally-approved medicines


Suspected side-effects of medicines that have been authorised by national regulators within the European Union (EU) can now be reported to a web-accessed database that has thus far focused on drugs with central EU market approvals.

EU patients and healthcare professionals are now being encouraged to make such reports on the 1,700 active substances in nationally-approved pharmaceuticals.

See more

You may also like

Regulatory

WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants

Read more
The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus AstraZeneca has received FDA approval for a once-weekly subcutaneous autoinjector formulation of Saphnelo for systemic lupus erythematosus, offering patients a more convenient alternative to the existing intravenous infusion
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    UK clinical trial reforms come into force in largest regulatory overhaul in 20 years The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
  4. UK REACH reform falls short as industry warns of £500m+ compliance bill The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little to support growth or innovation
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Britain's biotech potential (part I): world-class science, second-class support? The UK produces top-tier life sciences research, offers favourable conditions for early-stage investment and hosts a growing network of internationally competitive clusters. So why does the capital keep leaving?

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Regulatory

WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants

The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Regulatory

FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus

AstraZeneca has received FDA approval for a once-weekly subcutaneous autoinjector formulation of Saphnelo for systemic lupus erythematosus, offering patients a more convenient alternative to the existing intravenous infusion
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

UK clinical trial reforms come into force in largest regulatory overhaul in 20 years

The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Regulatory

FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection

The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Britain's biotech potential (part I): world-class science, second-class support?

The UK produces top-tier life sciences research, offers favourable conditions for early-stage investment and hosts a growing network of internationally competitive clusters. So why does the capital keep leaving?
Manufacturing

FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing

A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
Manufacturing

Precision meets innovation in melting point determination

Advancing analytical accuracy with automated thermal analysis
Subscribe now